RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
Our findings show that RET is overexpressed in ER+ metastatic breast cancer resistant to combined CDK4/6i and endocrine therapy, rendering RET inhibition a promising therapeutic approach for patients who experience disease progression on combined CDK4/6i and endocrine therapy.
Authors
- Sofie Traynor (ORCID: https://orcid.org/0000-0003-2565-5110)
- Henrik J. Ditzel (ORCID: https://orcid.org/0000-0003-3927-5135)
- Sidse Ehmsen (ORCID: https://orcid.org/0000-0002-4807-6325)
- Monique F. Hundebøl
- N I Nissen
- Benedetta Policastro (ORCID: https://orcid.org/0009-0005-1055-4503)
- Charlotte K. Kindt (ORCID: https://orcid.org/0000-0002-2667-8448)
- Mie K. Jakobsen (ORCID: https://orcid.org/0000-0001-7980-4623)
- Elsa Arbajian (ORCID: https://orcid.org/0000-0002-1484-0073)
- Johan Staaf (ORCID: https://orcid.org/0000-0001-5254-5115)
- Martin Bak (ORCID: https://orcid.org/0000-0002-6490-2519)
- Lene E. Johansen
- Carla L. Alves (ORCID: https://orcid.org/0000-0003-2266-9349)
Institutions
- University of Southern Denmark (DK)
- Lund University (SE)
- Odense University Hospital (DK)
- Hospital South West Jutland (DK)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.3389/fonc.2024.1497093
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Odense Universitetshospital
- Syddansk Universitet